Kobayashi Pharmaceutical Co (FRA:KOY) Cyclically Adjusted PS Ratio: (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KOY Kobayashi Pharmaceutical Co Ltd FRA:KOY
77 GF Score
Price €30.40
GF Value €26.16
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kobayashi Pharmaceutical Co  (FRA:KOY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms


Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Kobayashi Pharmaceutical Co Annual Data
Trend Mar16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.89 4.57 3.25 2.81 2.36

Kobayashi Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.40 2.37 2.36 2.58 0.00

FRA:KOY vs PG, CL, EL: Cyclically Adjusted PS Ratio Comparison

For the Household & Personal Products subindustry, Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


FRA:KOY
77GF Score
Kobayashi Pharmaceutical Co Ltd FRA:KOY
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Kobayashi Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Kobayashi Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/113.6000*113.6000
=0.000

Current CPI (Jun. 2026) = 113.6000.

Kobayashi Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 4.099 98.000 4.751
201612 4.663 98.400 5.383
201703 3.229 98.100 3.739
201706 3.726 98.500 4.297
201709 3.867 98.800 4.446
201712 4.649 99.400 5.313
201803 3.262 99.200 3.736
201806 3.832 99.200 4.388
201809 4.166 99.900 4.737
201812 5.123 99.700 5.837
201903 3.195 99.700 3.640
201906 3.933 99.800 4.477
201909 4.523 100.100 5.133
201912 4.975 100.500 5.623
202003 3.432 100.300 3.887
202006 3.619 99.900 4.115
202009 3.998 99.900 4.546
202012 4.606 99.300 5.269
202103 2.993 99.900 3.403
202106 3.547 99.500 4.050
202109 4.008 100.100 4.549
202112 4.743 100.100 5.383
202203 3.229 101.100 3.628
202206 3.529 101.800 3.938
202209 3.924 103.100 4.324
202212 4.753 104.100 5.187
202303 3.074 104.400 3.345
202306 3.444 105.200 3.719
202309 3.787 106.200 4.051
202312 4.611 106.800 4.905
202403 3.014 107.200 3.194
202406 2.901 108.200 3.046
202409 3.504 108.900 3.655
202412 4.269 110.700 4.381
202503 2.724 111.100 2.785
202506 2.939 111.700 2.989
202509 3.335 112.000 3.383
202512 3.957 113.000 3.978
202603 2.471 112.700 2.491
202606 0.000 113.600 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Kobayashi Pharmaceutical Co (FRA:KOY) Overvalued in 2026?

Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co stock appears to be overvalued. The current stock price of €30.40 is trading 16.2% above its estimated GF Value™ of €26.16. GuruFocus considers Kobayashi Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for FRA:KOY:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €26.16 vs. price of €30.40 (16.2% above fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the FRA:KOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kobayashi Pharmaceutical Co Business Description

Other Exchanges 4967:Japan
Address 4-4-10 Doshomachi, KDX Kobayashi Doshomachi Building, Chuo-ku, Osaka, JPN, 541-0045
Kobayashi Pharmaceutical Co Ltd is engaged in the manufacture and sale of healthcare products, daily necessities, and body warmers. The company operates through two reportable segments: Domestic Business and International Business, which handle production and sales activities in Japan and overseas, respectively. The company's product portfolio includes disposable body warmers, cooling gel sheets, OTC pharmaceuticals, oral hygiene products, air fresheners, eyeglass wipes, and deodorizing/household sundries.
77GF Score

Get the complete analysis for FRA:KOY

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.40
Price
€26.16
GF Value